Method for detection of human papillomavirus (HPV) for diagnostic purposes
AssigneeFerring B.V.
InventorsJoakim Dillner, Lena Dillner
Life of this patent
Estimating the term…
Abstract
Method for detection of infection with human papillomavirus (HPV) for diagnostic purposes, particularly for diagnosing carcinoma, or pre-stages thereof, or the risk of development of carcinoma. The detection is effected on a body fluid, particularly on a secretion from cervix uteri, by ascertaining the presence of IgA, IgG and IgM antibodies against papillomavirus virions, including individual virion proteins or peptides thereof, in the body fluid.
Claims41
A diagnostic method for detecting infection with papillomavirus (PV) in a body fluid or tissue which is useful for diagnosing PV-associated neoplasia, which comprises:
- a) reacting serum or other body fluid with papillomavirus protein selected from a group consisting of the L2-encoded approximately 64 kDa papillomavirus protein, the L1-encoded approximately 54 kDa papillomavirus protein, an approximately 28 kDa papillomavirus virion protein and an approximately 14 kDa papillomavirus virion protein;
- said papillomavirus protein having a sequence which is immunologically reactive with the antibody of said virus;
- b) forming a complex of said papillomavirus protein and human IgA antibodies;
- wherein the formation of human IgA antibody/protein complex is a confirmation for the presence of an infection with papillomavirus;
- and
- c) detecting said human IgA antibody-protein complex, wherein each protein is an isolated and purified protein.
A diagnostic method for detecting infection with papillomavirus (PV) in a body fluid or tissue which is useful for diagnosing PV-associated neoplasia, which comprises:
- a) forming an antibody-antigen complex by reacting serum or other body fluid with a late protein peptide which has the same epitope as a peptide having an amino acid sequence represented by a formula selected from the group consisting of:
- QVTFIYILVITCYENDVNVY (SEQ ID NO 1),
- PSEATVYLPPVPVSKVVSTD (SEQ ID NO 3),
- VVSTDEYVARTNIYYHAGTS (SEQ ID NO 4),
- HAGTSRLLAVGHPYFPIKKP (SEQ ID NO 5),
- PIKKPNNNKILVPKVSGLQY (SEQ ID NO 6),
- SGLQYRVFRIHLPDPNKFGF (SEQ ID NO 7),
- NKFGFPDTSFYNPDTQRLVW (SEQ ID NO 8),
- QRLVWACVGVEVGRGQPLGV (SEQ ID NO 9),
- VDNRECISMDYKQTQLCLIG (SEQ ID NO 12),
- LCLIGCKPPIGEHWGKGSPC (SEQ ID NO 13),
- KGSPCTNVAVNPGDCPPLEL (SEQ ID NO 14),
- PPLELINTVIQDGDMVHTGF (SEQ ID NO 15),
- VHTGFGAMDFTTLQANKSEV (SEQ ID NO 16),
- NKSEVPLDICTSICKYPDYI (SEQ ID NO 17),
- YPDYIKMVSEPYGDSLFFYL (SEQ ID NO 18),
- YIKGSGSTANLASSNYFPTP (SEQ ID NO 21),
- YFPTPSGSMVTSDAQIFNKP (SEQ ID NO 22),
- IFNKPYWLQRAQGHNNGICW (SEQ ID NO 23),
- NGICWGNQLFVTVVDTTRST (SEQ ID NO 24),
- TTRSTNMSLCAAISTSETTY (SEQ ID NO 25),
- SETTYKNTNFKEYLRHGEEY (SEQ ID NO 26),
- ITLTADVMTYIHSMNSTILE (SEQ ID NO 28),
- GGTLEDTYRFVTQAIACQKH (SEQ ID NO 30),
- ACQKHTPPAPKEDDPLKKYT (SEQ ID NO 31),
- LKKYTFWEVNLKEKFSADLD (SEQ ID NO 32),
- SADLDQFPLGRKFLLQAGLK (SEQ ID NO 33),
- QAGLKAKPKFTLGKRKATPT (SEQ ID NO 34),
- QLYKTCKQAGTCPPDIIPKV (SEQ ID NO 37),
- IIPKVEGKTIAEQILQYGSM (SEQ ID NO 38),
- PMDTFIVSTNPNTVTSSTPI (SEQ ID NO 49),
- GKSIGAKVHYYYDLSTIDPA (SEQ ID NO 57),
- and
- NNGLYDIYADDFITDTSTTP (SEQ ID NO 60),
- and which is immunoreactive with antibodies to the late protein peptide, as determined by competitive immunoassay, in an animal or human infected with papillomavirus, and
- b) detecting said antibody antigen complex, wherein the formation of mammalian antibody/antigen complex is a confirmation for the presence of an infection with papillomavirus.
Dependencies are inferred from the claim text.